

Index

- abiraterone, 236
 abuse. *See* childhood abuse; domestic violence and abuse
 accidents, ADHD increase in, 29–30
 acculturation, 72
 acquired immunodeficiency syndrome (AIDS), 199. *See also* human immunodeficiency virus
 activities of daily living (ADL), ADHD impairments in, 30
 AD. *See* Asperger disorder
 ADHD. *See* attention deficit hyperactivity disorder
 ADI-R, 12
 adjustment disorders, in cancer, 233–4, 238
 ADL. *See* activities of daily living
 adolescence, 45–7
 sex differences in brain development during, 5–6
 substance use in, 191–2
 characteristics of, 192
 interventions for, 192–3
 prevalence of, 192
 prevention approaches in, 193
 ADOS-2, 12
 adrenarche, 3–4, 44–5
 Adult ADHD Self Report Scale (ASRS), 35–6
 affective disorders. *See* mood disorders
 aggression
 PTSD association with, 107–8
 in schizophrenia, 63–5
 suicide association with, 122
 agoraphobia, 98–9
 AIDS. *See* acquired immunodeficiency syndrome
 AIS. *See* androgen insensitive females
 Alcohol, Smoking, and Substance Involvement Test (ASSIST), 197
 alcohol use, 197
 in adolescent males, 191–2
 characteristics of, 192
 interventions for, 192–3
 prevalence of, 192
 prevention approaches in, 193
 anxiety disorders with, 97–8
 in cardiovascular disease, 227
 domestic violence and abuse
 perpetration with, 180, 184
 HIV infection and, 206
 in male offenders, 163
 in middle adult males, 194
 characteristics of, 194–5
 interventions for, 195
 prevalence of, 194
 in older adult males, 195–6, 256–7
 characteristics of, 196
 interventions for, 196–7
 prevalence of, 196
 PTSD with, 107
 sex differences in, 191
 suicide association with, 122
 in young adult males, 193
 characteristics of, 193–4
 interventions for, 194
 prevalence of, 193
 alcohol-related dementia, 245–6
 5 α -reductase mutations, 47
 Alzheimer's disease, 241, 243, 245–7
 amenorrhea, 87
 amisulpride, for later life psychosis, 256
 amphetamines, for ADHD, 37–8
 amygdala
 androgen receptors in, 52–3
 sex differences in, 4–5
 AN. *See* anorexia nervosa
 anabolic steroid use, 90–1
 anabolic-androgenic steroid dependence, 90–2
 androgen insensitive females (AIS), 44
 androgen receptor (AR), 43–4, 52–3
 androgens. *See* dehydroepiandrosterone; dihydrotestosterone; testosterone
 androgynous individuals, 70
 anger
 in paternal postnatal depression, 140
 PTSD association with, 107–8
 angular gyrus, 4–5
 ANI. *See* asymptomatic neurocognitive impairment
 animal studies, sex differences in brain development, 1–3
 anorexia nervosa (AN), 86–7, 91
 anticipatory fear, 237–8
 antidepressants
 ASD comorbidity impacting, 17
 in BD, 154, 254–5
 for binge eating disorder, 91–2
 for depression and anxiety in HIV, 210–16
 for depression in cancer, 237
 for later life depression, 253
 neurogenesis with, 49–50
 for PTSD, 112
 sex differences in response to, 123–4, 134
 in stroke patients, 258
 antipsychotic drugs
 for ASD, 17
 for behavioural and psychological symptoms of dementia, 247
 for later life depression, 253
 for later life psychosis, 256
 sex differences in response to, 63
 substance use impacts on, 63
 antiretroviral therapy (ART), 199–202
 for depression and anxiety in HIV, 213–16
 psychiatric side effects of, 208–9
 antisocial personality disorder (APD)
 ADHD comorbidity with, 31
 domestic violence and abuse
 perpetration in, 180
 anxiety disorders
 ADHD symptoms mimicking, 36
 agoraphobia, 98–9
 in cancer, 233–4, 237–8
 cardiovascular disease association with, 222–6
 comorbidity associated with, 96–9
 ADHD, 31
 ASD, 14–15, 17
 BD, 152
 PTSD, 107
 conditions categorized as, 96
 GAD, 97, 237–8, 255–6
 HIV infection and, 207, 213–16
 aetiology of, 208–10
 diagnosis of, 210
 prevalence of, 207–8
 treatment of, 210–16
 in later life, 255–6
 migration association with, 72
 onset of, 48
 panic disorder, 97–8, 237–8

Index

- anxiety disorders (cont.)
 prevalence of, 73, 96–9
 in puberty, 52
 SAD, 52, 99
 sex differences in, 96, 101–2
 in TGDNB individuals, 82
- APD. *See* antisocial personality disorder
- APOE $\epsilon 4$ allele, 243
- AR. *See* androgen receptor
- aripiprazole
 for ASD, 17
 for BD, 153–4, 254–5
- ART. *See* antiretroviral therapy
- ASDs. *See* autism spectrum disorders
- Asperger disorder (AD), 10–11
- ASRS. *See* Adult ADHD Self Report Scale
- ASSIST. *See* Alcohol, Smoking, and Substance Involvement Test
- asymptomatic neurocognitive impairment (ANI), HIV associated, 202–4
- atomoxetine, for ADHD, 37–8
- attempted suicide, 119–20
- attention deficit hyperactivity disorder (ADHD), 25, 38
 adulthood persistence or emergence of, 25–6, 29, 31–2
 assessment of
 in adults, 35–6
 in children and adolescents, 34–5
 comorbidity in, 31–2
 ASD, 14–15, 17
 definitions of, 26–8
 domestic violence and abuse
 perpetration in, 180
 dopaminergic neurotransmission in, 4–5
 in DSM 5, 26–8, 35–6
 epidemiology of, 28–9
 historical context of, 25–6
 in ICD, 26–7
 impairments in, 29–31
 sex differences in
 brain development and, 7
 brain development and endocrine causes of, 33–4
 environmental and genetic causes of, 32–3
 impairments, 29–31
 prevalence, 29
 recognition and referral factors in, 34
 symptom domains for, 26–7
 treatment and management of, 36–8
- AUDIT, 197
- Australian Institute for Male Health and Studies, 123
- Australian National Health and Medical Research Council
 Centre for Excellence in Suicide Prevention, 123
- autism spectrum disorders (ASDs), 10, 17
 classification systems for, 11
 clinical assessment and diagnosis of, 11
 assessment tools and measures, 12–13
 developmental history, 11–12
 sex differences impacting, 12–14
 symptoms changes over lifespan, 13–14
- comorbid psychiatric disorders with, 14–15, 17
- gender dysphoria and, 79–80
- genetic and epigenetic factors in, 10
- interventions for, 15
 barriers to provision of, 17
 early, 15–16
 emotional regulation strategies, 16–17
 established treatments, 16
 individual tailoring of, 16–17
 neurocognitive functioning impacts on, 17
 social skill training, 16–17
- non-genetic risk factors in, 10–11
- outcomes of
 improvement of, 15–17
 vocational, behavioural and psychological, 14–15
- pharmacotherapy for, 17
- sex differences in
 brain development and, 7
 clinical assessment and diagnosis, 12–14
 prevalence, 10
- suicidal behaviour and, 122
- in TGDNB individuals, 82
- variability in presentation of, 10–11
- autistic disorder, 11
- bathrooms, gender identity and use of, 80–1
- BD. *See* bipolar affective disorder
- BDD. *See* body dysmorphic disorder
- BDI. *See* Beck Depression Inventory
- BDNF. *See* brain-derived neurotrophic factor
- Beck Depression Inventory (BDI), 141–2
- BED. *See* binge eating disorder
- behaviour, sex differences in
 brain function linked behaviours, 6
 dimensions of, 2–3
- behavioural activation
 for later life depression, 253
 for mental health disorders in cardiovascular disease, 226
- behavioural and psychological symptoms of dementia (BPSD), 246–7
- behavioural disorders, ASD
 comorbidity with, 14–15
- behavioural interventions, for mental health disorders in cardiovascular disease, 224–5
- Bem Sex Role Inventory (BSRI), 70
- benzodiazepines
 for depression and anxiety in HIV, 213
 for later life anxiety, 255–6
 misuse of, 257
- binary gender roles, 69–70
- binge eating, in bulimia nervosa, 87–8
- binge eating disorder (BED), 88–9, 91–2
- bipolar affective disorder (BD), 147, 155
 ADHD symptoms mimicking, 36
 aetiology and pathophysiology of, 147–9
 cardiovascular disease risk in, 222–3
 comorbidity associated with, 152–3
 course, impairment and prognosis of, 151–2
 diagnosis and types of, 150–5
 epidemiology, burden and costs of, 147–8
 in later life, 254–5
 in puberty, 52
 symptoms of, 149–50
 treatment of, 153
 other approaches, 154–5
 pharmacological interventions, 153–4
 principles of, 155
 psychological interventions, 154
- bipolar and related disorder due to another medical condition, 150
- Black Dog Institute, suicide prevention program of, 123
- bladder cancer, 234
- BN. *See* bulimia nervosa
- body dissatisfaction, body image disorders versus, 86
- body dysmorphic disorder (BDD), 79–80, 89
- body image disorders, 86, 92
 anabolic-androgenic steroid dependence, 90–2
 anorexia nervosa, 86–7, 91
 binge eating disorder, 88–9, 91–2
 body dissatisfaction versus, 86

- body dysmorphic disorder, 79–80, 89
- bulimia nervosa, 87–8, 91
- definition of, 86
- muscle dysmorphia, 89–92
- prevalence of, 86–9
- treatment for, 91–2
- borderline personality disorder (BPD)
- ADHD symptoms mimicking, 36
- BD with, 152
- domestic violence and abuse
- perpetration in, 180
- gender dysphoria and, 79–80
- in prisoners, 172
- bowel cancer, 235
- BPD. *See* borderline personality disorder
- BPSD. *See* behavioural and psychological symptoms of dementia
- brain connectivity
- in BD, 148–9
- in depression, 129–30
- sex differences in, 5
- brain development
- in ADHD, 33–4
- DHEA influence on, 44–5
- puberty-related changes, 52–3
- sex differences in, 1
- behaviours linked to brain function, 6
- connectivity, 5
- context-independent versus context-dependent, 2
- convergence versus divergence, 2
- cortical morphometry, 5
- developmental trajectories, 5–6
- dimensions of, 2–3
- dimorphic versus continuous, 2
- direct genetic effects on, 3
- direct versus indirect, 2
- epigenetic and environmental impacts on, 4
- hormonal effects on, 3–4, 43
- persistent versus transient, 2
- psychiatric disorder impacts of, 7
- structural, 4–5
- variability of, 2–3
- substance use impact on, 191–2
- brain injury, alcohol use and, 195
- brain pathology, in schizophrenia, 62
- brain structure
- in BD, 148–9
- sex differences in
- regional differences, 4–5
- total brain volume, 4
- brain-derived neurotrophic factor (BDNF)
- depression risk and, 51
- schizophrenia risk and, 61
- brief interventions, for substance use, 195
- BSRI. *See* Bem Sex Role Inventory
- bulimia nervosa (BN), 87–8, 91
- CAADID. *See* Conners Adult ADHD Diagnostic Interview for DSM-IV
- cancer, 232, 238
- anti-cancer treatment impacts in, 233–4
- existential and mental health challenges of, 232–3
- gender impact on, 232
- mental morbidities of specific, 234
- bladder, 234
- colorectal, 235
- head and neck, 235
- lung, 235–6
- penile, 236
- prostate, 236–7
- testicular, 236–7
- prevalence of mental morbidities in, 233–4
- treatment of mental morbidities in adjustment disorder, 238
- anxiety, 237–8
- depression, 237
- cannabis use
- HIV infection and, 206–7
- in middle adulthood, 194
- schizophrenia onset and, 63
- carbamazepine, for BD, 153
- cardiac rehabilitation, 228
- cardiovascular disease (CVD), 222–8
- anxiety association with, 222–6
- assessment of mental health in, 224
- burden of, 222
- dementia with, 223, 241, 245–6
- depression association with, 222–6, 252
- interventions for, 224–5, 227–8
- alcohol use, 227
- cardiac rehabilitation, 228
- depression and anxiety, 225–6
- diet and weight, 226
- partner support, 228
- sedentary lifestyle and physical inactivity, 227
- smoking, 227
- work stress, 228
- in men, 222–3
- risk factors for, 223–4
- caregivers
- ASD impact on, 15
- in dementia management, 247–8
- cART. *See* combination antiretroviral therapy
- caudate, 4–5
- CBT. *See* cognitive-behavioural therapy
- cell therapy, 172–3
- Center for Epidemiologic Studies Depression Scale (CES-D), 141–2
- central nervous system (CNS), HIV involvement of, 199–205
- CES-D. *See* Center for Epidemiologic Studies Depression Scale
- chest reconstruction surgery, for gender dysphoria, 81–3
- childhood abuse
- in depression and anxiety in HIV, 209–10
- in later life depression, 252
- mental impact of imprisonment and, 171
- in PTSD development, 109
- as risk factor in domestic violence and abuse, 178
- children, paternal postnatal depression impacts on, 139–40
- chlorpromazine, 173
- cholinesterase inhibitors, 247
- chronic medical conditions, behavioural and psychological symptoms of, 258
- cigarette smoking. *See* smoking
- citalopram, 123, 134
- for depression and anxiety in HIV, 210–13
- for depression in cancer, 237
- for later life anxiety, 255–6
- CJS. *See* Criminal Justice System
- clomipramine, for OCD, 100–1
- clonidine, for ADHD, 37–8
- clozapine, substance use impacts on, 63
- CNS. *See* central nervous system
- CNVs. *See* copy number variants
- cocaine, 205–6
- cognitive functioning
- in BD, 147–8, 151–2
- cardiovascular disease impact on, 223
- in dementia, 244–5, 247
- HIV infection and, 205
- asymptomatic neurocognitive impairment, 202–4
- dementia, 203–4
- diagnosis of, 204–5
- mild neurocognitive disorder, 202–4
- spectrum of, 202–3
- treatment of, 205
- in later life depression, 253
- in schizophrenia, 58, 62, 64
- sex differences in, 6

Index

- cognitive processing therapy (CPT), 112
- cognitive remediation programs, for schizophrenia, 64
- cognitive stimulation therapy, for dementia, 247
- cognitive-behavioural therapy (CBT)
 for anorexia nervosa and bulimia nervosa, 91
 for binge eating disorder, 91–2
 for depression, sex differences in response to, 123
 for depression and anxiety in HIV, 209–16
 for domestic violence and abuse perpetration, 183–4
 internet-based, 226
 for later life anxiety, 255–6
 for PTSD, 112
- colorectal cancer, 235
- combat exposure
 in domestic violence and abuse, 180
 in PTSD development, 109, 111
- combination antiretroviral therapy (cART), 199–202
 for depression and anxiety in HIV, 213–16
 psychiatric side effects of, 208–9
- common couple violence, 177
- communication theory, explanations of gender differences by, 70
- compensatory behaviours, in bulimia nervosa, 87–8
- compulsions, in OCD, 100
- compulsive exercise, in anorexia nervosa, 87
- conduct disorder, ASD comorbidity with, 14–15
- connectivity. *See* brain connectivity
- Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID), 35–6
- Cool Kids ASD intervention, 16–17
- copy number variants (CNVs), in serotonin transporter gene, 51
- cortical morphometry, sex differences in, 5
- cortical thickness, sex differences in, 4–5
- cortical thinning
 in ADHD, 33
 in puberty, 52–3
- cortisol
 depression risk and, 49–51
 in PTSD, 108
- court diversion, 164
- CPT. *See* cognitive processing therapy
- Criminal Justice System (CJS), 159, 166
 biases against men in, 159
- characteristics of men in contact with, 160–1
- factors associated with gender gap in, 159–60
- interventions for men in contact with, 164
 court diversion, 164
 custodial-based interventions and service models, 164–5
 forensic patients, 165–6
- mental health of men in contact with, 169–70
 diagnosis of, 172
 impact of imprisonment on, 171–4
 mass incarceration and, 170–1, 174
 potential solutions for, 173–5
 prison overcrowding impact on, 172–5
 self-harm and suicide, 163–4
 severe mental illness, 162–3
 sociocultural political context and, 170–1
 substance use disorders, 163
 toxic masculinity and, 171–2
 treatment of, 172–4
 rates of males versus females in, 159
- criminality, ADHD impact on, 29–30
- critical period, of foetal development, 3
- critical-time interventions, 165
- cross-sex-typed individuals, 70
- culture, 69
 clinical approaches and, 73–4
 gender concept and, 69–70
 psychiatric disorders in migrants, 71–2, 74
 in PTSD development, 109–10
 sexuality and role of sex across, 72–3
- custodial-based interventions and services, 164–5
- CVD. *See* cardiovascular disease
- cyclothymic disorder, 150
- cytokine induced sickness, 208
- cytokines
 in depression and anxiety in HIV, 208
 in PTSD, 108
- Darkness Visible* (Styron), 128
- DBS. *See* deep brain stimulation
- death threat, cancer as, 232–3
- deep brain stimulation (DBS), for BD, 154–5
- dehydroepiandrosterone (DHEA), 44–5
 depression risk and, 50
 in schizophrenia, 61–2
- delusions, in later life, 256
- dementia, 248
 alcohol-related, 245–6
 BD association with, 254
 behavioural and psychological symptoms of, 246–7
 cardiovascular disease with, 223, 241, 245–6
 causes of, 241, 245–6
 definition of, 241
 depression association with, 242–4, 253
 diagnosis and assessment of, 243–5
 global impact of, 241
 HIV associated, 203–4
 management of, 246–8
 behavioural and psychological symptoms, 247
 caregiver role in, 247–8
 cognitive symptoms, 247
 modifiable risk factors for, 242–3
 prevalence and incidence of, 241–2
 psychotic disorder association with, 256
- dementia with Lewy bodies, 245–6
- demoralization, in cancer, 233
- depression, 128. *See also* paternal postnatal depression
 ADHD symptoms mimicking, 36
 aetiology of, 130–3
 in cancer, 233–4, 237
 cardiovascular disease association with, 222–6, 252
 comorbidity associated with
 ASD, 14–15, 17
 PTSD, 107
 dementia association with, 242–4, 253
 emergency department identification of, 124
 HIV infection and, 207, 213–16
 aetiology of, 208–10
 diagnosis of, 210
 prevalence of, 207–8
 treatment of, 210–16
 in later life, 254
 clinical presentation and symptom course of, 252–3
 management of, 253–4
 prevalence, incidence and contributing factors of, 251–2
 testosterone in, 134–5, 252, 254
 maintenance of, 133
 “male,” 135
 in male offenders, 162–3
 masculinity as predictor of, 70
 migration association with, 72
 molecular genetics of, 133–4
 neurobiology of, 129–30
 onset of, 48

- personality and individual differences in, 132–3
 phenomenology and symptom patterns of, 129
 in prisoners, 172
 psychological treatments for, 135
 in puberty, 48–9
 endocrine factors in, 49–50
 genetic factors in, 50–2
 risk factors for, 48–9
 serotonergic neurotransmission in, 4–5
 sex differences in, 135
 aetiology, 132–3
 brain development and, 7
 incidence and prevalence, 130–1
 symptom patterns, 129
 in stroke patients, 258
 symptoms of, 128–9, 139
 in TGDNB individuals, 82
 treatment response in
 medications, 123–4, 134
 suicide risk and, 123–4
 testosterone, 134–5, 252, 254
 depressive episodes, in BD, 149–50, 154, 254–5
 desvenlafaxine, for depression in cancer, 237
 developmental delays, schizophrenia association with, 60–1
 developmental trajectories, sex differences in, 5–6
 dexamphetamine, for ADHD, 37–8
 DHEA. *See* dehydroepiandrosterone
 DHT. *See* dihydrotestosterone
 diabetes mellitus
 cardiovascular disease with, 222, 224
 dementia risk and, 242–3
 Diagnostic Interview for ADHD in Adults (DIVA), 35–6
 Diagnostic Statistical Manual of Mental Disorders Fifth Edition (DSM-5)
 ADHD in, 26–8, 35–6
 anorexia nervosa diagnostic criteria in, 87
 anxiety disorders in, 96–9
 ASD classification in, 11
 body dysmorphic disorder diagnostic criteria in, 89
 gender dysphoria in, 79
 major depression criteria in, 128–9, 139
 major neurocognitive disorder criteria in, 241
 muscle dysmorphia in, 90
 OCD in, 96, 99–100
 PTSD diagnostic criteria in, 106
 schizophrenia definition in, 58
 dialectical behaviour therapy, for suicide prevention, 124
 diet, in cardiovascular disease, 226
 diffusion tensor imaging (DTI), of sex differences in brain connectivity, 5
 dihydrotestosterone (DHT)
 brain development effects of, 4
 deficiency in, 47
 Dineh, gender roles of, 69
 discrimination
 in health care settings, 80–1
 TGDNB experience of, 80–2
 dissociative identity disorder, gender dysphoria and, 79–80
 DIVA. *See* Diagnostic Interview for ADHD in Adults
 DNA methylation, 4
 domestic violence and abuse (DVA), 177, 184
 definitions of, 177
 gender role stress in, 70–1, 74
 identification of, 181
 barriers to, 182–3
 enquiry of service users, 181–2
 perpetration, 182
 toolkit for, 181–2
 interventions for, 181, 183–4
 measurement issues in, 179
 perpetrators of, 177
 identification of, 182
 interventions for, 183–4
 male, 178
 mental disorders in, 179–81
 reporting bias in, 179
 victims of, 177
 interventions for, 183
 male, 177–8
 mental disorders in, 179
 donepezil, 247
 dopamine agonists, for BD, 153–4
 dopamine antagonists, for BD, 153–4
 dopamine depletion, in schizophrenia, 61
 dopaminergic neurotransmission, sex steroid effects on, 4–5
 drug use. *See* substance use
 DSM-5. *See* Diagnostic Statistical Manual of Mental Disorders Fifth Edition
 DSM-IV, ASD classification in, 11
 DTI. *See* diffusion tensor imaging
 duloxetine
 for depression in cancer, 237
 for later life anxiety, 255–6
 for later life depression, 253
 DVA. *See* domestic violence and abuse
 dyslipidaemia, in BD, 152–6
 eating disorders
 anorexia nervosa, 86–7, 91
 binge eating disorder, 88–9, 91–2
 bulimia nervosa, 87–8, 91
 in muscle dysmorphia, 90
 prevalence of, 86–9
 Eating Disorders Examination – Questionnaire (EDE-Q), 87
 Eating Disorders Inventory – 3 (EDI-3), 87
 ECT. *See* electroconvulsive therapy
 ED. *See* emergency department
 EDE-Q. *See* Eating Disorders Examination – Questionnaire
 EDI-3. *See* Eating Disorders Inventory – 3
 Edinburgh Postnatal Depression Scale (EPDS), 140–2
 educational achievement
 in ADHD, 30
 dementia risk and, 242–3
 in schizophrenia, 60–1
 e-health services, mental, 225–6
 eicosapentaenoic acid (EPA), 226
 electroconvulsive therapy (ECT)
 for BD, 154, 254–5
 for later life depression, 253–4
 embryo, sex differences in, 1, 43
 EMDR. *See* eye movement desensitisation and reprocessing
 emergency department (ED), suicide prevention strategies in, 124
 emotional distress, sex differences in, 73–4
 emotional regulation
 ADHD difficulties in, 31
 ASD interventions for, 16–17
 employment, ADHD impairments in, 30
 environmental factors
 in ADHD, 32–3
 in ASD, 10
 in depression, 130–2
 in schizophrenia, 58
 in sex differences in brain development, 4
 EPA. *See* eicosapentaenoic acid
 EPDS. *See* Edinburgh Postnatal Depression Scale
 epigenetic factors
 in ASD presentation, 10
 in depression onset, 48
 gender-differentiating actions of testosterone, 43–4
 in sex differences in brain development, 4

Index

- erectile dysfunction, 224
 escitalopram
 for depression and anxiety in HIV, 210–13
 for later life anxiety, 255–6
 esketamine, for BD, 154
 ethnicity, 69
 clinical approaches and, 73–4
 gender concept and, 69–70
 incarceration rates and, 160
 psychiatric disorders in migrants, 71–2, 74
 in PTSD development, 109–10
 sexuality and role of sex and, 72–3
 stresses related to masculinity and, 70–5
 evolutionary psychology
 anxiety vulnerability and, 101
 depression vulnerability and, 132–3
 exercise
 in bulimia nervosa, 87–8
 for cardiovascular disease, 227
 compulsive, in anorexia nervosa, 87
 dementia risk and, 242–3
 existential challenges, of cancer as, 232–3
 exposure-based therapies, for PTSD, 112
 expressivity, in anxiety disorders and OCD, 102
 eye movement desensitisation and reprocessing (EMDR), 112, 255–6

 FA. *See* functional anisotropy
 family. *See also* domestic violence and abuse
 support of, in cardiovascular disease, 228
 family homicides, 180–1
 family life
 ADHD impairments in, 30
 paternal postnatal depression impacts on, 139–40
 schizophrenia impact on, 63–5
 family-based therapy, for anorexia nervosa and bulimia nervosa, 91
 fathers, depression in new. *See* paternal postnatal depression
 FCR. *See* fear of recurrence
 fear. *See* anxiety disorders
 fear of recurrence (FCR), 237–8
 feminisation therapies, 81
 first responders, PTSD in, 109
 fluoxetine
 ASD comorbidity impacting, 17
 for BD, 154
 fluvoxamine, for later life anxiety, 255–6

 fMRI. *See* functional MRI
 foetal development, sex differences in, 3
 follicle-stimulating hormone (FSH), 3–4
 forensic patients
 interventions for, 165–6
 in state hospitals, 171
 frailty, in later life depression, 253
 Frascati criteria, 202–4
 frontal cortex, 4–5
 fronto-medial cortex, 4–5
 fronto-temporal dementia, 245–6
 FSH. *See* follicle-stimulating hormone
 functional anisotropy (FA), sex differences in brain connectivity, 5
 functional MRI (fMRI), of brain changes in puberty, 52

 GAD. *See* generalized anxiety disorder
 GAD-7. *See* Generalized Anxiety Disorder Scale
 galantamine, 247
 gender, sex versus, 1, 69, 77
 gender constructs, 69
 cultural differences in, 69–70
 gender diversity, 77, 80, 83
 gender dysphoria, 83
 aetiology of, 80
 diagnosis and presentation of, 79–80
 general issues relating to, 77
 management of, 80–2
 mental health issues associated with, 82
 outcomes of, 82–3
 prevalence of, 78–9
 psychological distress with, 73
 in puberty, 47
 terminology use in, 77–8
 gender identity
 in acculturation process, 72
 assigned sex incongruence with, 77
 bathroom use and, 80–1
 cultural differences in, 69–70
 elements of, 69
 self-determination of, 79
 sexual orientation association with, 72–3
 Gender Minority Stress Model, 82
 Gender Role Strain Theory, 70
 gender roles, 69–70
 in anxiety disorders and OCD, 101–2
 help-seeking behaviour and, 225
 muscle dysmorphia and, 90
 in PTSD symptom expression, 110
 role of sex in, 72–3

 stresses related to masculinity and, 70–5
 gender schema theory, 70
 genderqueer, 70
 General Health Questionnaire – 28 (GHQ), 141–2
 generalized anxiety disorder (GAD), 97
 in cancer, 237–8
 in later life, 255–6
 Generalized Anxiety Disorder Scale (GAD-7), 224
 genetic factors
 in ADHD, 32–3
 in ASD presentation, 10
 in BD, 148
 in depression, 130–4
 depression risk and, 50–2
 in schizophrenia, 58
 in sex differences in brain development, 3
 genital surgery, for gender dysphoria, 81–3
 GHQ. *See* General Health Questionnaire – 28
 glucocorticoids, depression risk and, 49–51
 glutamate toxicity, in schizophrenia, 61
 GnRH. *See* gonadotrophin releasing hormone
 GnRH agonists, puberty-delaying treatment with, 47
 gonadal steroids. *See* sex steroids
 gonadarche, 3–4
 gonadotrophin releasing hormone (GnRH), 3–4
 grey matter, 4–6
 guanfacine, for ADHD, 37–8

 HAD. *See* HIV-associated dementia
 HADS. *See* Hospital Anxiety and Depression Scale
 hallucinations, in later life, 256
 haloperidol, for BD, 153–4
 HAND. *See* HIV associated neurocognitive disorder
 harassment, in health care settings, 80–1
 HCL-32. *See* Hypomanic Checklist
 head and neck cancer, 235
 health care settings, discrimination in, 80–1
 heart rates, in anxiety disorders and OCD, 101
 hegemonic masculinity, 70
 help-seeking behaviour
 in dementia, 243–4
 in depression, 135
 masculinity and, 225
 in paternal postnatal depression, 143

- in PTSD, 111
 public health strategies encouraging, 124
 sex differences in, 73–4
 suicide risk and, 122
 heterochromatic sink, 3
 high functioning autism, 10
 clinical assessment and diagnosis of, 12
 comorbid psychiatric disorders with, 14–15
hijra, 69, 72–3
 HIV. *See* human immunodeficiency virus
 HIV associated neurocognitive disorder (HAND), 205
 asymptomatic neurocognitive impairment, 202–4
 dementia, 203–4
 diagnosis of, 204–5
 mild neurocognitive disorder, 202–4
 spectrum of, 202–3
 treatment of, 205
 HIV-associated dementia (HAD), 203–4
 homicide, perpetrators of, 180–1
 homophobia, internalized, 73, 79–80
 homosexuality, emergence of, 47
 hopelessness, 121
 hormonal effects
 in ADHD, 33–4
 in anxiety disorders and OCD, 101
 in BD, 147–9
 depression risk and, 49–50
 in older adults with depression, 134–5, 252, 254
 in PTSD, 108–9
 in schizophrenia, 61–2
 in sex differences in brain development, 3–4, 43
 hormone therapy
 for gender dysphoria, 81–2
 testosterone replacement, 134, 252
 Hospital Anxiety and Depression Scale (HADS), 224
 5HTT. *See* serotonin transporter
 human immunodeficiency virus (HIV), 216
 aging impacts of, 199–202
 anxiety and depression in, 207, 213–16
 aetiology of, 208–10
 diagnosis of, 210
 prevalence of, 207–8
 treatment of, 210–16
 biology of, 199–200
 cognition and ageing of people living with, 199–202
 comorbidities of, 199
 historical perspective of, 199
 life expectancy of people living with, 199–202
 mental health aspects of, 201–2
 neurocognitive impairment in, 205
 asymptomatic neurocognitive impairment, 202–4
 dementia, 203–4
 diagnosis of, 204–5
 mild neurocognitive disorder, 202–4
 spectrum of, 202–3
 treatment of, 205
 neuropathogenesis of, 201
 prevalence and incidence of, 199
 substance misuse and, 205, 207
 alcohol, 206
 cannabinoids, 206–7
 cocaine, 205–6
 methamphetamine, 206
 opioids, 206
 treatment of, 207
 systemic infection with, 200–1
 hyperactivity, in ADHD, 25–7, 29
 hyperkinetic syndrome, 25–6
 hypertension, dementia risk and, 242–3
 Hypomanic Checklist (HCL-32), 150
 hypomanic episodes, in BD, 149–50, 254
 hypothalamus
 androgen receptors in, 52–3
 sex differences in, 4–5
 iCBT. *See* internet-based CBT
 ICD. *See* International Classification of Disease
 illicit drug use. *See* substance use
 immunological factors, in depression and anxiety in HIV, 208
 imprisonment. *See* prison
 impulsivity, in ADHD, 25–7, 29
 inattention, in ADHD, 25–7, 29
 incarceration. *See* prison
 incidence, definition of, 58–9
 inclusive practice, in health care settings, 80–1
 Incompetent to Stand Trial (IST), 171
 Indigenous peoples, incarceration rates for, 160
 inflammation, depression risk and, 49–50
 inflammatory markers
 in BD, 147–9
 in PTSD, 108
 informant history, for dementia diagnosis, 244
 informed consent model of care, for gender dysphoria, 81
 Insanity Defense, 169
 instrumentality, in anxiety disorders and OCD, 102
 integrase inhibitors, 199
 intellectual disability, in ASD, 10
 International Classification of Disease (ICD)
 ADHD in, 26–7
 anxiety disorder category in, 96
 dementia definition of, 241–8
 gender dysphoria in, 79
 muscle dysmorphia in, 90
 OCD in, 96, 99–100
 PTSD diagnostic criteria in, 106
 schizophrenia definition in, 58
 internet search behaviour, suicide risk and, 122, 124
 internet-based CBT (iCBT), 226
 interpersonal function. *See* social function
 interpersonal trauma, in PTSD development, 109
 intimate partner homicides, 180–1
 intimate partner violence (IPV), 177.
 See also domestic violence and abuse
 intimate terrorism, 177
 intracranial volume, in schizophrenia, 62
 IPV. *See* intimate partner violence
 irritability
 in paternal postnatal depression, 140
 PTSD association with, 107–8
 IST. *See* Incompetent to Stand Trial
 jail. *See* prison
 job performance
 in OCD, 100
 in schizophrenia, 60–1
 ketamine, for BD, 154
 kisspeptin, 44
 Klinefelter syndrome, 3
 lamotrigine, for BD, 153, 254–5
 language barriers, in clinical interventions, 74
 later life, 258
 anxiety disorders in, 255–6
 behavioural and psychological symptoms of chronic medical conditions in, 258
 bipolar disorder in, 254–5
 depression in, 254
 clinical presentation and symptom course of, 252–3
 management of, 253–4

Index

- later life (cont.)
 prevalence, incidence and contributing factors of, 251–2
 testosterone in, 134–5, 252, 254
 HIV infection in, 199–205
 life expectancy and
 gender gap in, 251
 mental health impact on, 251
 psychotic disorders in, 256
 substance use in, 195–6, 256–7
 characteristics of, 196
 interventions for, 196–7
 prevalence of, 196
 suicide in, 257–8
 learning disorders, ADHD comorbidity with, 31
 LGBT communities, psychological distress in, 73
 LH. *See* luteinizing hormone
 life expectancy
 gender gap in, 251
 mental health impact on, 251
 of people living with HIV infection, 199–202
 light therapy, for BD, 154–5
 lisdexamfetamine
 for ADHD, 37–8
 for binge eating disorder, 91–2
 lithium, for BD, 153, 254–5
 lorazepam, for depression and anxiety in HIV, 213
 lung cancer, 235–6
 lurasidone, for BD, 154
 luteinizing hormone (LH), 3–4

 magnetic resonance imaging (MRI), of brain changes in puberty, 52–3
 major depression episode (MDE), 128–9
 major depressive disorder (MDD)
 aetiology of, 130–3
 cardiovascular disease risk in, 222–3
 maintenance of, 133
 “male depression,” 135
 molecular genetics of, 133–4
 personality and individual differences in, 132–3
 psychological treatments for, 135
 risk factors for, 48–9
 endocrine, 49–50
 genetic, 50–2
 sex differences in, 135
 aetiology, 132–3
 incidence and prevalence, 130–1
 symptom patterns, 129
 symptoms of, 128–9, 139
 treatment response in
 medications, 123–4, 134
 suicide risk and, 123–4
 testosterone, 134–5, 252, 254

 major neurocognitive disorder. *See also* dementia
 DSM-5 criteria for, 241
 male, definition of, 77
 “male depression,” 135
 man, definition of, 77
 manic episodes, in BD, 149–50, 153–4, 254
 MAOA, ADHD link with, 33
 marital status, dementia risk and, 243
 Masculine Gender-Role Stress Questionnaire (MGRS), 70–1
 masculinisation therapies, 81
 masculinity
 in anxiety disorders and OCD, 101–2
 clinical approaches and, 73–4
 emotional distress and, 73–4
 hegemonic, 70
 help-seeking behaviour and, 225
 role of sex in, 72–3
 stresses related to, 70–5
 toxic, 69–70, 171–2
 mass incarceration, 170–1, 174
 MAST. *See* Michigan Alcohol Screening Test
 mastery, in anxiety disorders and OCD, 102
 maternal depression, paternal postnatal depression and, 140, 143
 maternal deprivation, 48
 MCI. *See* mild cognitive impairment
 MDD. *See* major depressive disorder
 MDE. *See* major depression episode
 MDQ. *See* Mood Disorders Questionnaire
 melatonin, 17
 memantine, 247
 memory concerns, in dementia, 244–5
 men who have sex with men (MSM)
 domestic violence and abuse in, 177–8
 psychological distress in, 73
 menopause, schizophrenia onset after, 61
 mental health courts, 164
 methamphetamine (meth), 206
 methylphenidate, for ADHD, 37–8
 MGRS. *See* Masculine Gender-Role Stress Questionnaire
 Michigan Alcohol Screening Test (MAST), 197
 middle adulthood, substance use in, 194
 characteristics of, 194–5
 interventions for, 195
 prevalence of, 194
 migration, psychiatric disorder association with, 71–2, 74

 mild cognitive impairment (MCI), 245
 mild neurocognitive disorder (MND), HIV associated, 202–4
 military populations
 domestic violence and abuse in, 180
 PTSD in, 109, 111
 minority groups. *See* ethnicity
 minority masculinity stress theory, 72–3
 mirtazapine
 for depression and anxiety in HIV, 210–13
 for depression in cancer, 237
 mixed states, in BD, 149–50
 MND. *See* mild neurocognitive disorder
 molecular genetic studies, of depression, 133–4
 mood disorders. *See also* bipolar affective disorder; depression
 ADHD comorbidity with, 31
 ADHD symptoms mimicking, 36
 ASD comorbidity with, 14–15, 17
 in cancer, 233–4, 237
 dementia risk and, 242–3
 sex differences in prevalence of, 73
 in TGDNB individuals, 82
 Mood Disorders Questionnaire (MDQ), 150
 mood stabilizers, 153–4, 254–5
 mortality rates
 ADHD-associated increase in, 29–30
 depression-associated increase in, 133
 motivational interviewing, for mental health disorders in cardiovascular disease, 224–5
 motor cortex, 4–5
 MRI. *See* magnetic resonance imaging
 MSM. *See* men who have sex with men
 muscle dysmorphia, 89–92
 muxe, 69

 narrative therapy, 74
 National Institute for Health and Care Excellence (NICE)
 ADHD conclusions of, 26, 37
 guidance on domestic violence and abuse intervention, 183
 negative symptoms, in schizophrenia, 58, 61–4
 neopterin, in depression and anxiety in HIV, 208
 neurobiology
 of BD, 147–9
 of depression, 129–30
 of depression and anxiety in HIV, 208–9

- neurodevelopmental pattern, of
 schizophrenia in males, 62, 64–5
- neurogenesis, depression risk and,
 49–50
- neuroleptics, sex differences in
 response to, 63
- neuronal density, sex differences in, 5
- Neuropsychiatric Inventory (NPI), 246
- neuroticism, depression risk and,
 132–3
- NICE. *See* National Institute for Health
 and Care Excellence
- non binary gender roles, 69–70
- non-suicidal self-injury, 119–20
- North American Indigenous tribes,
 gender roles of, 69
- NPI. *See* Neuropsychiatric Inventory
- obesity
 in cardiovascular disease, 226
 dementia risk and, 242–3
- obsessions, in OCD, 100
- obsessive-compulsive disorder (OCD)
 categorization of, 96, 99–100
 comorbidity associated with, 100
 ASD, 17
 early onset, 100–1
 functional impairment in, 100
 in later life, 255–6
 obsessions and compulsions in, 100
 prevalence of, 96, 100
 sex differences in, 100–2
 treatment response in, 100–1
- obstetric complications, schizophrenia
 association with, 60–1
- occupational exposures, in PTSD
 development, 109
- occupational function. *See* work
 function
- OCD. *See* obsessive-compulsive
 disorder
- oestradiol, brain development effects
 of, 4
- oestrogens
 brain development effects of, 3–4
 in schizophrenia, 61–2
- offenders, 159, 166
 biases against male, 159
 characteristics of, 160–1
 factors associated with gender gap in,
 159–60
 interventions for, 164
 court diversion, 164
 custodial-based interventions and
 service models, 164–5
 forensic patients, 165–6
 mental health of, 169–70
 diagnosis of, 172
 impact of imprisonment on, 171–4
- mass incarceration and, 170–1,
 174
 potential solutions for, 173–5
 prison overcrowding impact on,
 172–5
 self-harm and suicide, 163–4
 severe mental illness, 162–3
 sociocultural political context and,
 170–1
 substance use disorders, 163
 toxic masculinity and, 171–2
 treatment of, 172–4
 rates of male versus female, 159
- olanzapine, for BD, 153–4, 254–5
- older adults. *See also* later life
 HIV infection in, 199–205
 life expectancy of
 gender gap in, 251
 mental health impact on, 251
 testosterone in, depression treatment
 and, 134–5, 252, 254
- online mental health services, 225–6
- opioid misuse
 HIV infection and, 206
 in later life, 257
- oppositional defiant disorder, ASD
 comorbidity with, 14–15
- orbitofrontal cortex, 4–5
- over-the-counter medications, misuse
 of, 257
- oxazepam, for depression and anxiety
 in HIV, 213
- “pains of imprisonment,” 171
- Panic Attack Treatment in Comorbid
 Heart Diseases (PATCHD), 226
- panic disorder, 97–8
 agoraphobia with, 98
 in cancer, 237–8
- paralimbic brain region, 4–5
- parasuicide, 119–20
- parent training, for ADHD, 37
- parent-child interaction, ASD impact
 on, 15
- parenthood, transition into, 139–40.
See also paternal postnatal
 depression
- Parkinson's disease, 258
- partner. *See also* domestic violence and
 abuse
 loss of, 252
 support of, in cardiovascular disease,
 228
- PATCHD. *See* Panic Attack Treatment
 in Comorbid Heart Diseases
- paternal postnatal depression (PPND),
 139, 144
 bio-psycho-social factors associated
 with risk for, 140
- care provider role in, 143
 child and family effects of, 139–40
 concept of, 139
 perinatal partnering with fathers
 and, 144
 prevention and management of
 active strategies, 140–2
 administrative strategies, 142
 passive strategies, 142
 screening, 140–2
 websites for fathers with, 144
- Patient Health Questionnaire (PHQ),
 224
- PBQ. *See* Postpartum Bonding
 Questionnaire
- PDD-NOS. *See* pervasive
 developmental disorder not
 otherwise specified
- PDE-5 inhibitors. *See* phosphodiesterase-5
 inhibitors
- PE. *See* prolonged exposure
- penile cancer, 236
- perineuronal nets, 48
- perpetrator programs, 183–4
- personality, depression risk and, 132–3
- pervasive developmental disorder not
 otherwise specified (PDD-
 NOS), 11
- pesticide poisoning, 120
- phosphodiesterase-5 (PDE-5)
 inhibitors, 236
- PHQ. *See* Patient Health Questionnaire
- physical appearance, dissatisfaction
 with, 86. *See also* body image
 disorders
- physical assault. *See also* childhood
 abuse; domestic violence and
 abuse
 in prison, 171–2
- physical inactivity
 in cardiovascular disease, 227
 dementia risk and, 242–3
- plea of insanity, 169
- poisoning, suicide and self-harm by,
 120–1
- positive symptoms, in schizophrenia,
 58
- posterior parietal cortex, 4–5
- postnatal depression. *See* paternal
 postnatal depression
- Postpartum Bonding Questionnaire
 (PBQ), 141–2
- post-release support, for offenders, 165
- posttraumatic stress disorder (PTSD),
 106
 classification of, 96
 comorbidity associated with, 107–8
 development of
 biological underpinnings in, 108–9

Index

- posttraumatic stress disorder (PTSD) (cont.)
 occupational exposures in, 109
 prevalence rates across lifespan, 108, 110
 prior interpersonal trauma in, 109
 social and cultural factors in, 109–10
 in later life, 255–6
 nature of, 106
 in prison, 173
 recovery and prognosis for, 113
 sex differences in, 113
 assessment and diagnosis impacts of, 111
 help-seeking and support, 111
 prevalence, 107–10
 symptom expression, 110–11
 treatment of
 innovations in, 112–13
 pharmacological interventions, 112–13
 psychological interventions, 112–13
 PPND. *See* paternal postnatal depression
 pregabalin, for later life anxiety, 255–6
 prescription drug misuse, in later life, 257
 prevalence, definition of, 58–9
 prison
 characteristics of men in, 160–1
 factors associated with gender gap in, 159–60
 mental health of men in, 169–70
 diagnosis of, 172
 impact of imprisonment on, 171–4
 mass incarceration and, 170–1, 174
 potential solutions for, 173–5
 prison overcrowding impact on, 172–5
 self-harm and suicide, 163–4
 severe mental illness, 162–3
 sociocultural political context and, 170–1
 substance use disorders, 163
 toxic masculinity and, 171–2
 treatment of, 172–4
 mental health service provision in, 164–5
 rates of males versus females in, 159
 prison reform, 174
 progesterone, in schizophrenia, 61–2
 prolonged exposure (PE), 112
 prostate cancer, 236–7
 protease inhibitors, 199
 pseudodementia, 244
 psychiatric disorders. *See also specific disorders*
 sex differences in brain development impacting, 7
 psychophysiological studies, of anxiety disorders and OCD, 101
 psychosis. *See also* schizophrenia
 domestic violence and abuse
 perpetration in, 180–1
 in later life, 256
 in male offenders, 162–3
 in prisoners, 172
 psychosocial function, in
 schizophrenia, 63–4
 psychosocial gender constructs, 69
 cultural differences in, 69–70
 psychostimulants. *See* stimulants
 PTSD. *See* posttraumatic stress disorder
 puberty, 43, 53
 adolescence behavioural characteristics and, 45–7
 adrenarche and, 44–5
 androgen receptor and, 43–4
 anxiety disorders in, 52
 behaviours associated with, 45
 bipolar disorder in, 52
 brain changes related to, 52–3
 depression in, 48–9
 endocrine factors in, 49–50
 genetic factors in, 50–2
 hormonal effects in, 3–4
 medical delay of, 47
 onset of, 44–5
 sexuality and gender difficulties in, 47
 in utero testosterone secretion impacts on, 43
 public health strategies
 for prevention of adolescent substance use, 193
 for suicide prevention in men, 123–4
 purging behaviours, in bulimia nervosa, 87–8
 quality of life
 ADHD impact on, 30–1
 BD impact on, 147–8
 quetiapine, for BD, 153–4, 254–5
 racism, psychiatric disorder association with, 71–2
 rapid-cycling bipolar affective disorder, 151
 RDoC. *See* Research Domains Criteria
 rehabilitative ideal, 174
 relationships, ADHD impairments in, 30
 repetitive transcranial magnetic stimulation (rTMS), for BD, 154–5
 rescue workers, PTSD in, 109
 Research Domains Criteria (RDoC), for depression, 129–30
 residential care setting, dementia in, 248
 RESPECT, on identification of intimate partner violence, 181–2
 reverse transcriptase inhibitors, 199
 risky behaviour
 in adolescence, 46–7
 emotional distress masked by, 73
 in MSM, 73
 risperidone
 for ASD, 17
 for BD, 153–4, 254–5
 rivastigmine, 247
 routine/ritualistic behavioural impairments and sensory sensitivities (RRBI), in ASD, 11
 rTMS. *See* repetitive transcranial magnetic stimulation
 SAD. *See* social anxiety disorder
 same-sex relationships, domestic violence and abuse in, 177–8
 schizoaffective disorder, 59
 schizophrenia, 58
 ASD comorbidity with, 14–15
 cardiovascular disease risk in, 222–3
 construct of, 58
 dopaminergic neurotransmission in, 4–5
 gender dysphoria and, 79–80
 in later life, 256
 migration association with, 71–2
 sex differences in, 64–5
 age of onset, 59–61
 brain development and, 7
 brain differences, 62
 cognition differences, 58, 62, 64
 hormone differences, 61–2
 incidence and prevalence, 58–9
 long term outcomes, 64
 premorbid functioning, 60–1
 psychosocial functioning, 63–4
 substance abuse, 63–5
 suicide rates, 64
 symptom profile, 63
 treatment response, 63
 treatment options for, 64
 school performance
 ADHD impairments in, 30
 in schizophrenia, 60–1
 SCID. *See* Structured Clinical Interview for DSM Disorders
 Secret Agent Society, 16–17
 sedentary lifestyle, 227

- selective serotonin reuptake inhibitors (SSRIs)
 ASD comorbidity impacting, 17
 for BD, 254–5
 for depression and anxiety in HIV, 210–13
 for depression in cancer, 237
 for later life depression, 253
 in prostate cancer, 236
 for PTSD, 112
 sex differences in response to, 123
- self-harm, 119
 epidemiology of, 120–1
 factors associated with, 121–2
 in male offenders, 163–4
 sex differences in, 125
 prevention and treatment
 implications of, 123–5
 putative mechanisms for, 123
 terminology related to, 119–20
- self-injurious behaviour, 119–20
- serotonergic neurotransmission, sex
 steroid effects on, 4–5
- serotonin, depression risk and, 51–2
- serotonin transporter (5HTT),
 depression risk and, 51
- serotonin-norepinephrine reuptake
 inhibitors (SNRIs), for PTSD, 112
- sertraline, for later life anxiety, 255–6
- sex, gender versus, 1, 69, 77
- sex chromosomes, 1
 ADHD sex differences linked to, 32–3
 direct effects on sex differences by, 3
 sex differences. *See specific topics*
- sex steroids. *See also specific hormones*
 brain development effects of, 1, 3–4, 43
 brain regional differences linked to, 4–5
 in schizophrenia, 61–2
- sex-typed individuals, 70
- sexual assault. *See also childhood abuse*;
 domestic violence and abuse
 in prison, 171–2
- sexual orientation
 gender identity association with, 72–3
 psychological distress and, 73
 in PTSD development, 109–10
- sexual rehabilitation, in prostate
 cancer, 236
- sexuality
 cultural differences in, 72–3
 emergence of, 47
- sildenafil, 236
- situational violence, 177
- sleep apnoea
 cardiovascular disease with, 223
 dementia risk and, 243
- smoking
 in adolescents, 192
 in cardiovascular disease, 227
 dementia risk and, 242–3
 in later life, 256–7
 lung cancer risk and, 235–6
 in schizophrenia, 63
- SMSS. *See* Subjective Masculinity Stress
 Scale
- SNRIs. *See* serotonin-norepinephrine
 reuptake inhibitors
- social anxiety disorder (SAD), 99
 in puberty, 52
- social cognition
 puberty-related changes in, 52–3
 in schizophrenia, 62, 64
- social communication deficits, in ASD, 11
- social constructionist approaches,
 explanations of gender
 differences by, 70
- social function
 in OCD, 100
 in prison, 172
 in schizophrenia, 60–1, 63–4
- social learning theory, explanations of
 gender differences by, 70
- social phobia, 99
- social skill training, for ASD, 16–17
- social support
 in cardiovascular disease, 228
 PTSD and, 109–11
- Social Thinking, 16–17
- somatosensory cortex, 4–5
- spouse. *See also* domestic violence and
 abuse
 loss of, 252
 support of, in cardiovascular disease,
 228
- Sry gene, 1, 3, 43
- SSRIs. *See* selective serotonin reuptake
 inhibitors
- state asylums, 169–70, 174
- mass incarceration and, 170–1
- steroid dependence, 90–2
- steroid use, 90–1
- stigma
 of anabolic steroid use, 90
 of anorexia nervosa, 87
 of gender dysphoria, 79, 82
 of HIV infection, 209–16
 of substance use, 196–7
- stimulants
 for ADHD, 36–8
 ASD comorbidity impacting, 17
- stoma, 235
- street gangs, 46
- stress
 in cardiovascular disease, 228
 masculinity-related, 70–5
- physiological reactivity to, 101
 sex differences in response to, 2, 61
 suicide association with, 121
- Stress Response Syndrome, 172
- stroke, depression association with,
 258
- structural connectome, sex differences
 in, 5
- Structured Clinical Interview for DSM
 Disorders (SCID), 150
- Styron, William, 128
- Subjective Masculinity Stress Scale
 (SMSS), 71
- substance use, 197. *See also* alcohol use
 in adolescent males, 191–2
 characteristics of, 192
 interventions for, 192–3
 prevalence of, 192
 prevention approaches in, 193
- comorbidity associated with
 ADHD, 31
 anxiety disorders, 97
 BD, 152
 PTSD, 107
 schizophrenia, 63–5
- domestic violence and abuse
 perpetration in, 180–1, 184
- emotional distress masked by, 73
- HIV infection and, 205, 207
 alcohol, 206
 cannabinoids, 206–7
 cocaine, 205–6
 methamphetamine, 206
 opioids, 206
 treatment of, 207
- in male offenders, 163
- in middle adult males, 194
 characteristics of, 194–5
 interventions for, 195
 prevalence of, 194
- in older adult males, 195–6, 256–7
 characteristics of, 196
 interventions for, 196–7
 prevalence of, 196
- sex differences in, 191
 suicide association with, 122
- in young adult males, 193
 characteristics of, 193–4
 interventions for, 194
 prevalence of, 193
- substance/medication-induced bipolar
 and related disorder, 150
- suicide, 119
 in BD, 152
 in depression, 133
 epidemiology of, 120
 factors associated with, 121
 in later life, 257–8
 in male offenders, 163–4

Index

- suicide (cont.)
 male rates of, 69, 71
 in post-release period, 165
 in prison, 173
 in schizophrenia, 64
 sex differences in, 125
 prevention and treatment
 implications of, 123–5
 putative mechanisms for, 122–3
 terminology related to, 119
 in TGDNB individuals, 83
 surface area, brain, 4
 synaptic density, sex differences in, 5
- tadalafil, 236
 TCAs. *See* tricyclic antidepressants
 TD. *See* testosterone deficiency
 technology, mental health
 interventions via, 225–6
 telehealth, PTSD treatment using, 112–13
 telomeres, HIV shortening of, 202
 temazepam, for depression and anxiety
 in HIV, 213
 testes, development of, 1, 43
 testicular cancer, 236–7
 testosterone
 in ADHD, 33–4
 adolescence behavioural
 characteristics and, 46–7
 androgen receptor and, 43–4
 anxiety disorders and, 52
 in anxiety disorders and OCD, 101
 in BD, 147–9
 behavioural effects of, 45
 brain development effects of, 1, 3–4, 43
 brain regional differences linked to, 5
 depression risk and, 49–50
 in older adults with depression,
 134–5, 252, 254
 in PTSD, 108
 in puberty onset, 44–5
 in puberty-related brain changes, 52–3
 in schizophrenia, 61–2
 in utero secretion of, 43
 testosterone deficiency (TD), 135
 TGDNB. *See* trans, gender diverse and
 non-binary
 third gender roles, 69, 72–3
 Thorazine, 173
 thyroid dysfunction, in BD, 152–6
 tic disorders, ASD comorbidity with,
 14–15
- tolerance, to anabolic steroids, 91
 topiramate, for binge eating disorder,
 91–2
 total brain volume, 4
 Tourette's syndrome, 7
 toxic masculinity, 69–70
 in prisons, 171–2
 trans, gender diverse and non-binary
 (TGDNB), 70
 discrimination experienced by,
 80–2
 gender dysphoria in, 77
 aetiology of, 80
 diagnosis and presentation of,
 79–80
 management of, 80–2
 mental health issues associated
 with, 82
 outcomes of, 82–3
 prevalence of, 78–9
 puberty in, 47
 terminology use by, 77–8
 transinstitutionalization, 169–71
 transphobia, 82
 transsexualism, 78
 transvestic fetish, 79–80
 trauma exposure, 106–7, 109, 180. *See*
 also posttraumatic stress disorder
 in depression and anxiety in HIV,
 209–10
 mental impact of imprisonment and,
 171
 tricyclic antidepressants (TCAs)
 ASD comorbidity impacting, 17
 for later life depression, 253
 tryptophan, in depression and anxiety
 in HIV, 208
 tumor. *See* cancer
 twin studies, of depression aetiology,
 130–2
- undifferentiated individuals, 70
 unemployment, suicide association
 with, 122–3
- vagus nerve stimulation (VNS), for BD,
 154–5
 valproate, for BD, 153, 254–5
 vardenafil, 236
 vascular dementia, 223, 241, 245–6
 vascular depression, 252
 vegetarian diets, 226
- venlafaxine
 for later life anxiety, 255–6
 for later life depression, 253
 ventricular volume, in schizophrenia,
 62
 veterans, PTSD in, 109, 111
 vicarious reinforcement, gender
 differences developed through,
 70
 violence. *See also* domestic violence
 and abuse
 emotional distress masked by,
 73
 gender role stress in, 70–1, 74
 PTSD association with, 107–8
 violent offences, factors associated with
 gender gap in, 159
 virtual reality (VR), PTSD treatment
 using, 112–13
 VNS. *See* vagus nerve stimulation
 voice therapy, for gender dysphoria,
 81
 VR. *See* virtual reality
- weight loss, for cardiovascular disease,
 226
 white matter, 4–6
 widowhood, depression risk in, 252
 withdrawal, from anabolic steroids,
 91
 work function
 in OCD, 100
 in schizophrenia, 60–1
 work stress, in cardiovascular disease,
 228
 World Professional Association for
 Transgender Health (WPATH),
 81
- X chromosome, 1, 3
 X-linked genes, ADHD differences
 linked to, 32–3
 XXY disorders, 3
 XYY disorders, 3
- Y chromosome, 1, 3
 Y-linked genes, ADHD differences
 linked to, 32–3
 young adulthood, substance use in, 193
 characteristics of, 193–4
 interventions for, 194
 prevalence of, 193